Vitasora Health Limited · ASX:VHL
Vitasora Health — Investor Presentation (June 2026)
27 slides from Vitasora Health's investor presentation, Jun 11, 2026
Slide 1: A New Leadership Team, a New Scalable Platform & ~40K Patient List
For personal use only A New Leadership Team, a New Scalable Platform & ~40K Patient List Driving Vitasora's Next Phase of Growth Proven US healthcare leaders, embedded patient growth opportunities and the vCare platform are accelerating revenue growth and creating a clear pathway to cashflow breakev
Slide 2: Important notice & disclaimer
Important notice & disclaimer For personal use only This presentation has been prepared by Vitasora Health Limited (ASX: VHL) (“Vitasora” or “the Company”). It is provided for information purposes only and does not constitute an offer of securities, a prospectus, product disclosure statement, cleans
Slide 3: Growth Proven. Scale Emerging. Profitability in Sight.
EXECUTIVE SUMMARY Growth Proven. Scale Emerging. Profitability in Sight. For personal use only ~US$190K* ~78% ~$275K ~$9,500 $650K/mth targeted breakeven Sept May monthly Fee For vCare* Total share of revenue Estimated May RECORD per Business Day Qtr FFS + UPEC and TOC Service Revenue Aprmonthly 70%
Slide 4: Multiple competitive advantages driving sustainable growth
WHY NOW · MARKET SIZE Multiple competitive advantages driving sustainable growth 01 02 03 For personal use only Embedded Growth Within Existing Structural Regulatory Tailwinds Technology Advantage Compounding Clients 2026 CMS rule changes — 2-reading RPM, 10- 40,000 patients in existing client relat
Slide 5: A clear pathway to scalable revenue growth and profitability
A clear pathway to scalable rev enue gro wth and pro fitability Fee-For-Service programs are the dominant driver of growth, margin and cashflow 72% 40,000 patients For personal use only $70K-$180K Existing revenue drivers in 2026 & contracts Revenue driven by FFS up from 44% in Sept Monthly revenues
Slide 6: A Large and Expanding US Healthcare Opportunity
For personal use only 02 OP P ORTUNITY A Large and Expanding US Healthcare Opportunity Leveraging technology, clinical expertise and operational excellence to drive sustainable growth. Vitasora Health Limited · Investor Presentation 6
Slide 7: A multi-billion-dollar market expanding rapidly through 2030
WHY NOW · MARKET SIZE A multi-billion-dollar market expanding rapidly through 2030 For personal use only $35.0B Independent research forecasts a US$6–$29B US RPM market by 2030 $30.0B $25.0B • US RPM market reaching US$6.3B–29.1B by 2030, at $20.0B 12.6–18.4% CAGR. $15.0B • Even 2% of the broader se
Slide 8: Total Addressable Market - US healthcare system embraces prevention
THE CHAL L ENGE Total Addressable Market - US healthcare system embraces prevention to reduce need For personal use only 2025 Total US healthcare spend was 68.2M patients Eligible for CCM & RPM $5.6T, a 7.1% increase over 2024 35.1 M Medicare Advantage 33.1 Traditional Medicare 40M - 46M Medicare Be
Slide 9: 2026 CMS reimbursement tailwinds
THE CMS OPPORTUNITY – D RIVING CARE TRANSFORMATION 2026 Centers of Medicare & Medicaid Services (CMS) reimbursement tailwinds According to CMS claims data and third-party evaluations by Mathematica, CMS expects a cost reduction of approximately $4 for every $1 invested in Chronic Care Management (CC
Slide 10: CMS is accelerating the shift to preventative care
THE CMS OPPORTUNITY – D RIVING CARE TRANSFORMATION CMS is accelerating the shift to preventative care – Vitasora is built to benefit For personal use only RPM & CCM Revenue Aligned to Integrated Platform with vCare Lower Cost Through Continuous Care Engagement A fully integrated Electronic Medical R
Slide 11: A massive market hiding in plain sight
A massive market hiding in plain sight 97% of Medicare patients remain untapped PRIMARY FOCUS 3% For personal use only Primary Care of eligible patients on CCM today Federally Qualified Health Centers (FQHCs), Rural Health Centers & Direct Primary Care <1% of eligible patients on RPM today Largest u
Slide 12: Growth is already embedded in existing client base
SATISTIED EXISTING CL IENTS – P ATHWAY TO P ROFITABIL ITY Growth is already embedded in existing client base 4 REVENUE GROWTH LEVERS 1 Capture Additional Patient Pool from Existing Satisfied Clients For personal use only ~40,000 untapped patients across 4 current clients. No new sales required — onl
Slide 13: Both volume and rate are driving the result
For personal use only 03 OP ERATING P ERFORM ANCE Both volume and rate are driving the result Vitasora Health Limited · Investor Presentation 13
Slide 14: Vitasora's Profitability Engine Is Scaling Rapidly
OP ERATING PERFORMANCE · SAL ES MOMENTUM Vitasora's Profitability Engine Is Scaling Rapidly For personal use only Core FFS / Ceras vCare platform V +63% FFS billings up 63%, validating the path to $200,000 $180,000 breakeven $160,000 $140,000 $120,000 • Sept-25 $117K → May-26 ~$190K (+63%). $100,000
Slide 15: Record Revenue Productivity Signals Scaling Economics
OP ERATING PERFORMANCE · OP ERATING L EVERAGE Record Revenue Productivity Signals Scaling Economics May delivered the highest revenue per business day in company history. For personal use only $10,000 May delivered ~$9,500/business day $9,500 — +72% on CY2025 V $9,000 $8,500 $8,000 • May ~US$9,500/b
Slide 16: Revenue yield per billed patient increased 35%
OP ERATING PERFORMANCE · YIEL D EXP ANSION Revenue yield per billed patient increased 35% For personal use only $73.00 Yield per billed patient +35% — operating leverage in the model $68.00 $63.00 • US$49 → US$67 per billed patient (Jul-25 → Mar-26). • Each billed patient generates more billable act
Slide 17: Increasing Revenue Per Patient Through Deeper Clinical Engagement
OP ERATING PERFORMANCE · CARE INTENSITY Increasing Revenue Per Patient Through Deeper Clinical Engagement For personal use only CPT per billed patient 1.56 → 1.90 2.00 (+22%); objective 2.5 by Sept, 3.0 by 1.90 1.90 year-end 1.80 1.70 • CPT codes per patient 1.56 (Jul-25) → 1.90 (Mar-26), 1.60 +21.7
Slide 18: Growth momentum accelerating
OP ERATING PERFORMANCE · L EAD ING IND ICATOR Growth momentum accelerating For personal use only 1800 Onboarding volumes have roughly doubled in two months 1600 1400 +113% 900 June • April/May 879 new enrolments. 1200 Forecast • Onboarding leads next-quarter billable revenue. 1000 800 0 • Post-vCare
Slide 19: Fee For Service Patient volumes scaling across the platform
OP ERATING PERFORMANCE · P ATIENT VOL UMES Fee For Service Patient volumes scaling across the platform For personal use only 5,000 Active patients +43.8%, enrolled 4,500 programs +38.1% in nine months 4,000 3,500 • Active patients +43.8%, programs +38.1% (Jul-25 → Mar- 3,000 26). 2,500 • Latest conf
Slide 20: Three revenue lines, a forecast, and the path to breakeven
For personal use only 03 OUTL OOK Three revenue lines, a forecast, and the path to breakeven Vitasora Health Limited · Investor Presentation 20
Slide 21: Three lines of revenue: pathway to profitability
OUTLOOK · REVENUE L INES 3 lines of revenue: FFS + UPEC* + TCM. Pathway to profitability For personal use only $700,000 Core FFS growth accelerates driving recurring revenue $600,000 $500,000 • June FFS revenue of $250K. $400,000 • April (470), May (410), June (900), July & August (1,500) $300,000 e
Slide 22: Realised cost transformation: 29% reduction in monthly OpEx
OUTLOOK · PATH TO P ROFITABIL ITY Realised Cost transformation — US$833K to US$591K: a 29% reduction in monthly OpEx For personal use only $3.0M Realized Cost Bridge driven by vCare & upgraded systems $2.5M $2.5M $0.7M $2.0M • Qtrly total cost base US$2.5M (Q1, FY26) → US$1.77M (Apr 26): a realized
Slide 23: Life Time Value (LTV) / Customer Acquisition Cost (CAC)
UNIT ECONOMICS · L TV / CAC Life Time Value (LTV) / Customer Acquisition Cost (CAC) — Every patient acquired creates significant long-term value 9.0x For personal use only 6.0x LTV/CAC 8.0x 7.8x Attractive economics today. Stronger as vCare scales. 7.0x 6.0x 6.0x • Base 6.0× - LTV ~US$2,400 from CAC
Slide 24: Experienced executive and operational US healthcare management team
OUR TEAM Experienced executive and operational US healthcare management team Nicholas Smedley 14 years at UBS and KPMG. Transaction experience from Marjan Mikel 30+ years experienced global healthcare executive. Led For personal use only Non-Executive Chairman A$9B WMC Resources to Catch.com.au. Cha
Slide 25: Base Case Revenue reaching $1.4M/month in mid-2027
OUTLOOK · FORECAST Base Case Revenue reaching $1.4M/month in mid-2027 with an upside of $2.2M For personal use only Target EBITDA margin of 20% by Q2 $5,850,000 CY2027 $5,400,000 $4,950,000 vCare Launch $4,500,000 40K pnt List $4,050,000 — 20% EBITDA margin by Q2 CY2027 $3,600,000 — Significant majo
Slide 26: The Offer: Use of proceeds
THE OFFER Use of proceeds Investment highlights A$1.50M Patient Management & Account Mgmt Sales & Marketing $700K $425K Private placement — oversubscriptions accepted at the board’s sole discretion. vCare Enhancement & Roll out $150K Working Capital $150K For personal use only Costs of the Offer $75
Slide 27: Thank you
For personal use only Thank you For further information, investors and media please contact: Mr Marjan Mikel Mr Nicholas Smedley CEO & Managing Director Non-Executive Chairman Vitasora Health Limited Vitasora Health Limited P: +61 408 462 873 P: +61 447 074 160 E: marjan@vitasorahealth.com E: nichol